Connecting clinical care, data and research
PartnershipsContact
← Back to publications

RESEARCH PUBLICATION / 2026

Original Article

New oral anticoagulants and liver cancer risk in patients with chronic liver disease

New oral anticoagulants and hepatocellular carcinoma among patients with HBV, HCV, and alcoholic liver diseases: a nationwide cohort study.

Hepatology international

Citation & Authors

Hepatol Int. 2026;.

Yu-Wen Su; Yu-Hsuan Pai; Yao-Min Hung; Fuu-Jen Tsai; Renin Chang; Sung-Shuo Kao

ABSTRACT · RESEARCH SUMMARY

Research summary

This Taiwanese National Health Insurance study matched 14,666 pairs of NOAC and warfarin users with HBV, HCV, or alcohol-related liver disease. NOAC use was associated with a lower risk of hepatocellular carcinoma (aHR 0.47; 95% CI 0.26–0.85). The association was more pronounced in HCV and alcohol-related liver disease but was not significant in the HBV subgroup. Missing information on liver disease severity, viral activity, and adherence limits causal interpretation.

Key points based on the public abstract; this is a reading guide, not a full abstract translation.Read original abstract ↗